Genetic Testing Integration Panels (GTIPs): A Novel Approach for Considering Integration of Direct‐To‐Consumer and Other New Genetic Tests into Patient Care by Uhlmann, Wendy R. & Sharp, Richard R.
PROFESSIONAL ISSUES
Genetic Testing Integration Panels (GTIPs): A Novel
Approach for Considering Integration of Direct-To-Consumer
and Other New Genetic Tests into Patient Care
Wendy R. Uhlmann & Richard R. Sharp
Received: 1 August 2011 /Accepted: 8 December 2011 /Published online: 14 January 2012
# National Society of Genetic Counselors, Inc. 2012
Abstract There has been a dramatic increase in the number
of genetic tests available but few tests have practice guide-
lines. In addition, many tests have become available outside
of clinical settings through direct-to-consumer (DTC) com-
panies and several offer tests not considered standard of
care. To address several practical challenges associated with
the rapid introduction of clinical and DTC genetic tests, we
propose that genetic counselors and geneticists organize
expert panels in their institutions to discuss the integration
of new tests into patient care. We propose the establishment
of Genetic Testing Integration Panels (GTIPs) to bring to-
gether local experts in medical genetics, genetic counseling,
bioethics and law, health communication and clinical labora-
tory genetics. We describe key features of this approach and
consider some of the potential advantages and limitations of
using a GTIP to address the many clinical challenges raised by
rapidly emerging clinical and DTC genetic tests.
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Managing a Deluge of New Genetic Tests
Recent advances in human genetics have produced expo-
nential increases in the number of genetic tests available to
clinicians. In 1999, the year the White House announced the
completion of the initial draft of the human genome, there
were approximately 700 clinical genetic tests available
(GeneTests 1993–2010). By June 2011, over 2300 genetic
tests were listed in the GeneTests database, an increase of
more than 200% (GeneTests 1993–2010). To our knowl-
edge, no other medical specialty has been faced with the
introduction of several hundred new tests in such a short
time period. This dramatic expansion in genetic tests
available to clinicians has not been accompanied by proper
vetting of all tests nor a corresponding increase in the
number of practice guidelines. Without such guidance,
individual genetic counselors, clinical geneticists, and other
healthcare professionals face challenging decisions about
the utilization of novel genetic tests, particularly when a
test’s sensitivity and clinical implications have not been
firmly established by peer-reviewed studies.
Very few genetic tests have been formally evaluated by
either of the two major professional societies that support
clinical genetics professionals in the United States, the
American College of Medical Genetics (ACMG) and the
National Society of Genetic Counselors (NSGC). As of June
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2011, the ACMG had released 15 disease/phenotype-specif-
ic standards and guidelines, 27 practice guidelines, and 23
policy statements (American College of Medical Genetics
2011a, b, c). The NSGC, as of June 2011, had issued 11
practice guidelines and 13 position statements, several of
which deal with broader issues (e.g. nondiscrimination or
recurrent miscarriages) and not testing for specific genetic
conditions (National Society of Genetic Counselors 2011a,
b). Many of these ACMG and NSGC guidelines and policy
statements were published several years ago, and may no
longer be up-to-date given advances in testing for specific
genetic conditions, declining sequencing costs and the emer-
gence of newmethodologies to test for hundreds of conditions
simultaneously, and changing societal attitudes about genetic
testing. Indeed, in a rapidly changing field like genetics, it is
no longer reasonable to expect that professional societies can
establish test-specific practice guidelines that keep pace with
the introduction of new tests. The development of practice
standards and guidelines is a time-consuming process, often
taking years and requiring multiple expert and committee
reviews prior to their adoption by an appropriate medical
board or professional organization.
The lack of professional guidance on the use of genetic
tests and oversight of genetic testing has also been recognized
by the federal government. Efforts to address these issues
included the appointment of the Secretary’s Advisory Com-
mittee on Genetic Testing (SACGT) in 1999 (Secretary’s
Advisory Committee on Genetic Testing 2011) and subse-
quently the Secretary’s Advisory Committee on Genetics,
Health and Society (SACGHS) in 2002 (Secretary’s Advisory
Committee on Genetics, Health and Society 2011). In addi-
tion, EGAPP (Evaluation of Genomic Applications in Practice
and Prevention) was initiated by the Centers for Disease
Control and Prevention (CDC) in 2004 to establish an
evidence-based process for evaluating genetic tests and their
clinical application (Teutsch et al. 2009). The SACGT and
SACGHS committees have since been disbanded. As of
September 2011, EGAPP had issued eight evidence reports
and six recommendations regarding use of genetic tests (Eval-
uation of Genomic Applications in Practice and Prevention
Initiative 2011a, b). The genetic testing reports and recom-
mendations of these groups took years to complete for just a
few conditions and while helpful, have still left major gaps in
providing guidance about the use of genetic tests.
The introduction of multiplex tests and eventually whole
genome sequencing, which yield a large volume of results,
means that the traditional approach to pre- and post-test
counseling and informed consent will need to be reassessed
and new approaches developed (Sharp 2011). As daunting
as these challenges may seem, they are perhaps more diffi-
cult still when one considers that many genetic tests are now
available outside of clinical settings. A number of direct-to-
consumer (DTC) genetic testing companies have been
established over the past several years. According to the
Genetics and Public Policy Center, as of May 28, 2010, 29
DTC companies were offering a range of genetic testing
products and services. (Genetics & Public Policy Center
2010). While some of the tests offered DTC are also offered
in clinical settings, many are not, including nutrigenomic
tests, tests for specific traits (e.g. athletic ability) and tests
evaluating risks of developing complex diseases (e.g. dia-
betes) based on association studies for which there currently
is not sufficient evidence to support clinical use.
There are many factors to consider in deciding whether
genetic testing is clinically indicated, which specific test is
most appropriate, and which laboratory to utilize (Faucett
and Ward 2009; Uhlmann 2009). For DTC tests, patients
can decide to have genetic testing done independently with-
out any involvement from a healthcare provider and without
consideration of their personal or medical history to deter-
mine whether testing is in fact clinically indicated. Patients
may have DTC genetic testing and then contact their health-
care providers to request assistance in interpreting test
results (Giovanni et al. 2010; Powell et al. 2011). The
healthcare provider is placed in the difficult situation of
not being consulted before the patient initiated genetic test-
ing and then being asked afterwards to assess the potential
implications of results from tests that are not considered
standard of care. Of concern is also the problem of misat-
tributed equivalence where patients and physicians can po-
tentially think the results of a DTC genetic test are as robust
and accurate as a clinically ordered genetic test (Eng and
Sharp, 2010). Patients may also be falsely reassured by DTC
results which put them at low risk and as a result, decline
clinically recommended genetic testing.
The volume of data in genetic test reports can amount to a
number of pages and be overwhelming to both patients and
healthcare providers. Most healthcare providers, including
specialists in genetics, have limited familiarity with DTC
tests and the population-based genome-wide association
studies (GWAS) that are used to establish the provided risk
estimates. In addition, knowledge of statistics may be limit-
ed and understanding differences between risks presented as
relative risks, absolute risks and odds ratios may be confus-
ing. Compounding interpretation is the fact that the same
sample sent to different companies can yield different results
(Ng et al. 2009; United States Government Accountability
Office 2010). Although existing genetics professional
organizations’ statements on DTC testing all urge caution
in using these tests, none provide specific guidance about
how to counsel the patient seated in front of you requesting
interpretation of their test results (American College of
Medical Genetics 2008; American Society of Human Ge-
netics 2007; National Society of Genetic Counselors 2007).
As a result, individual practitioners are left to struggle with
the interpretation of DTC results on their own.
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To address some of the practical challenges associated
with the significant increase in clinical and DTC genetic
tests and rapid pace of their introduction, we propose that
genetics professionals consider organizing expert panels in
their institution or local genetics community to discuss
testing issues and begin developing guiding principles and
points to consider for the use in patient care of new genetic
tests and even existing genetic tests with no practice guide-
lines. These expert panels can complement the work of
genetics professional organizations and inform the develop-
ment of future practice guidelines.
We propose the creation of local Genetic Testing Integra-
tion Panels (GTIPs) that draw together available experts in
medical genetics, genetic counseling, bioethics and law,
health communication and clinical laboratory genetics. We
see GTIPs as providing a local mechanism to obtain input
on global issues regarding the use of genetic tests and
helping to address the absence of guidance resulting from
the rapid pace of test introduction and lack of practice
guidelines. We describe key features of this approach and
consider some of the potential advantages and limitations of
using a GTIP to address global testing issues and assist in
managing the many clinical challenges raised by rapidly
emerging clinical and DTC genetic tests.
Origins of the Approach: From Translational Bioethics
Research to Genomic Integration
The approach we describe has its origins in a research
study examining genetics professionals’ views regarding
the return of diagnostic results from new forms of ge-
netic testing titled “Presenting Diagnostic Results from
Large-Scale Clinical Mutation Testing” (R01 HG004500;
PI: Sharp RR). This study, funded by the Ethical, Legal
and Social Implications (ELSI) Program of the National
Human Genome Research Institute, sought to character-
ize how genetics professionals view the types of diag-
nostic possibilities and the results that should be
discussed with patients in the context of very large-
scale forms of mutation analysis. Participants in this
R01 study were invited to participate in a series of four
two-hour Working Group meetings over an 18-month
period in which they were asked to: 1) consider the
potential utility of various clinical applications of highly
multiplexed forms of genetic testing, 2) discuss practical
challenges associated with the interpretation and commu-
nication of results from highly multiplexed forms of
genetic testing, 3) identify ethical and legal considera-
tions raised by the use of genomic tests in patient care
settings, and 4) describe their overall levels of enthusi-
asm and concern regarding emerging forms of genomic
testing. The more global aim of the study was to
develop effective pre- and post-test counseling strategies
for discussing results from highly multiplexed forms of
genetic testing.
To increase the practical relevance of Working Group
discussions, detailed case studies were used to examine
how genetics professionals would approach challenging
clinical situations, such as how to disclose and explain
results to patients when genetic testing is done for a very
large number of genetic conditions, how to address ambig-
uous results or how to return incidental findings that are not
directly relevant to the testing indication. These case studies
included a summary of a hypothetical patient’s case history,
as well as an anonymous laboratory report. Participants
were asked to consider how they would prepare for a clinical
appointment in which they would present these test results
to a patient and provide counseling about their interpreta-
tion. To allow for an extended and clinically nuanced dis-
cussion of relevant practical considerations, each two-hour
session focused on just 2–3 case studies. Individual case
studies examined currently available genetic tests and were
developed to examine both clinically administered and DTC
products (Table 1).
Working Groups were established in six US cities where
there are well established programs in medical genetics and
translational genomic research: Ann Arbor, Michigan; Bal-
timore, Maryland; Cleveland, Ohio; Denver, Colorado; Phil-
adelphia, Pennsylvania; and Seattle, Washington. To
promote diversity across study sites, we selected these cities
based on their geographical location, current training pro-
grams in medical genetics and genetic counseling, genomic
research programs, and clinical practice settings (e.g. pedi-
atric vs. adult clinics, public vs. private institutions, etc.). At
each site, we recruited nine to twelve specialists in genetics
to serve as members of these Working Groups. In addition to
clinical geneticists and genetic counselors, Working Groups
typically included specialists in bioethics, health communi-
cation, law, primary-care medicine, and directors of clinical
genetics laboratories. Working Group discussions were un-
dertaken as a research activity, which was approved by the
appropriate Institutional Review Boards at each study site.
Participants provided written consent to participate in the
study as a Working Group member and received a modest
honorarium for their participation.
Sessions were facilitated by the principal investigator
(RRS). Working Group discussions were audiotaped and
transcribed to enable qualitative analysis. Although data
analysis is ongoing, we recognized that these Working
Groups could be useful outside of research settings, as a
unique forum for exploring how novel genetic tests might be
integrated into clinical practice. This opinion was voiced by
several Working Group participants as well, who com-
mented that they would like to continue meeting after the
study ended: “We want to try to continue. … We don’t all
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get together [very often] and just to have these discussions
with the different perspectives has been very valuable.”
We found that these Working Groups provided a neutral
environment where the challenges raised by new genetic
testing options could be openly discussed. Most of the
Working Groups, whether from the same or different insti-
tutions, included genetics professionals who tended not to
work closely together and practiced in different clinics in-
cluding, adult, pediatrics, cancer and reproductive genetics.
The Working Groups also included experts from outside the
genetics community, who brought different perspectives
than genetics clinicians and through their input and clarify-
ing questions helped participants think more globally about
current and future approaches to genetic testing and patient
care. For several Working Group members, these sessions
also provided them with their first opportunity to review
multiplexed genetic test results and reports from DTC test-
ing laboratories.
We believe that having an outside facilitator frame ques-
tions for discussion promoted an openness among partici-
pants and helped to “level the playing field” with respect to
differences of power that can exist between physicians and
non-physicians and between those in medical and non-
medical professions. The result was a rich discussion of
relevant issues, in which all participants were encouraged
and felt empowered to share their respective opinions with-
out fear of dismissive reactions by others and in a supportive
setting that encouraged creative thinking. Working Group
discussions also fostered a more academic engagement of
relevant challenges, with much greater emphasis on
Table 1 A sample clinical case scenario to facilitate GTIP discussions of chromosomal microarray results
Chief Complaint: Laboratory Results (discussed in detail in the anonymous lab report):
A 3 year old boy presents to a genetics clinic to discuss chromosomal
microarray (CMA) results which revealed a finding of unclear clinical
significance.
Abnormal male karyotype; finding of unclear clinical significance
confirmed via FISH: del (6)(q26q26)RP11_168A5. Deletion also
observed in the patient’s father.
Clinical Background: Background on PARK2 Gene:
Patient originally presented to Neurology for evaluation of
developmental delay and autistic behaviors. When genetic test results
identified a chromosomal deletion of unclear significance, the
Neurology service ordered parental testing and referred the patient to
Genetics for interpretation of results. Between that time and the time of
the patient’s appointment with Genetics, parental results indicated that
the deletion was inherited from the patient’s father. Included in the
patient’s/father’s deletion is the PARK2 gene. The patient is scheduled
to be seen by Genetics with his mother but the father gave permission
for his results to be discussed.
• PARK2-related Parkinson Disease (PD) is an autosomal recessive
condition.
• If a person has two abnormal PARK2 genes, he or she is expected to
develop PD prior to age 40 and occasionally before age 20.
• The test result cannot confirm if the patient’s non-deleted PARK2 gene
has a mutation (unlikely); if it does, he is expected to develop early-
onset/juvenile PD.
• Generally, genetic testing for adult-onset conditions is not recommen-
ded for asymptomatic minors when no preventive interventions are
available.
Medical History: • The patient’s other PARK2 gene is likely normal as is the case for most
autosomal recessive conditions. However, several studies suggest that
in PARK2-related PD some people with a heterozygous deletion go on
to develop PD, usually at a later age than people with two abnormal
genes.
• Mild facial changes, notably dental anomalies including congenital
absence of a lower mandibular incisor.
• There is no current therapy available to prevent the development of PD.
• Recurrent Otitis Media with last episode in December 2010.
• GERD as an infant.
• History of blood in stools as an infant, associated with formula usage.
Family History:
Full brother, 1 year of age, healthy and developing normally.
Paternal half-brother, 7 years of age; walked at 17 months and had an
early speech delay; cognitive development is now age-appropriate.
Mother: 35 years of age, medical history notable for depression and
hypertension; no developmental or neurological concerns.
Sample Questions:
Other maternal relatives: histories unremarkable for neurological
disease.
1. Suppose you were scheduled to meet with this patient in your clinic
tomorrow, how would you prepare for that appointment?
Father: 36 years of age, history notable for Crohn’s disease; no
developmental or neurological concerns.
2. How would you describe the uncertainties associated with these
genetic test results?
Other paternal relatives: medical histories unremarkable; no tremors/
neurological disorders.
3. What information would you want to communicate to the patient’s
mother? To the patient’s father?
Social History:
4. Suppose the patient’s father is unavailable for discussion of his test
result, what steps (if any) would you take to ensure that the patient’s
father is notified about his abnormal test result?
• Patient lives with his parents and two brothers.
• Mother works part-time for family business and father is a teacher.
5. In your opinion, was it appropriate for the Neurology service to have
ordered parental testing? If not, what steps could be taken to reduce the
chance of this happening again in the future?
• Patient currently attending a special education preschool program.
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intellectual debate and discussion than is typically available
within the confines of a specific genetics clinic. Of note,
there was considerable consistency of approach across the
six Working Groups, particularly with respect to their identi-
fication of pertinent challenges associated with emerging clin-
ical and DTC genetic tests. In particular, Working Group
participants consistently drew attention to challenges of pre-
test counseling for tests that generate a diverse range of results,
such as test products that evaluate both rare and common
disease associations. Similarly, participants consistently
expressed concerns about their ability to stay abreast of new
DTC testing options and interpret results from these tests.
Creating a Genetic Testing Integration Panel (GTIP)
Based on our personal experiences working with clinical
genetics professionals in the context of the study described
above, and the feedback we received from our Working
Group members, we recommend that genetic counselors
and geneticists consider establishing a GTIP at their institu-
tion. The purpose of the GTIP would be to establish an
environment in which genetics professionals can come to-
gether with experts outside their respective clinics and per-
sonal areas of expertise to consider how best to manage the
many clinical issues and implementation challenges associ-
ated with emerging clinical and DTC genetic tests.
A well-organized GTIP could provide advice on both
system integration challenges and genetic counseling dilem-
mas associated with novel genetic tests (Table 2). In addi-
tion to considering these global issues, a GTIP could
provide the opportunity for clinicians to share their experi-
ences and approaches using novel genetic tests and factors
considered and addressed pre- and post-testing. The GTIP
could provide a forum for multiple clinicians and experts to
weigh in on cases that pose particularly difficult interpretive,
diagnostic or ethical challenges. Some of the practical issues
a GTIP might consider include: How should the many
potential results from multiplex forms of genetic testing be
discussed in pre-test counseling sessions? How many genet-
ic findings or genetic risk factors is it reasonable to review in
a single counseling session? What communication methods
tend to be most effective in promoting patient retention of
large amounts of genetic information over time? In addition,
GTIPs may be useful in establishing standard approaches to
system integration challenges, such as whether DTC results
should be routinely included in a patient’s medical record or
how to determine appropriate utilization of costly genetic
tests and evolving tests, such as whole-genome or exome
sequencing.
These panels of local experts in clinical genetics could
incorporate many of the key elements of the Working
Groups described above. For example, GTIPs could include
genetics professionals working in different clinical settings,
directors of clinical genetics laboratories, and specialists in
related fields such as bioethics and health communication;
GTIP discussions could also be organized around case stud-
ies that highlight dilemmas or specific challenges associated
with emerging clinical and DTC genetic tests; and, finally,
GTIPs could be moderated by someone who is not directly
involved in the day-to-day operations of a genetics clinic to
encourage more open communication among members.
This way of structuring a GTIP also has parallels to tumor
Table 2 Examples of clinical challenges raised by multiplexed and
DTC genetic tests
System Integration
Challenges
• What expertise is needed to order multiplexed
genetic tests? Can primary care physicians
order these tests or should these tests be
ordered by geneticists and other specialists?
• How many genetic findings or genetic risk
factors is it reasonable to review in a single
counseling session?
• How should results of multiplexed and DTC
genetic tests be documented in patients’
medical records?
• Genetic testing is a moving target. Is the
physician who ordered the test obligated to
recontact the patient in the event that new
information is learned about the significance
of the patient’s test results?
• What types of educational outreach and
physician support are needed for utilization of
new genetic tests?
• Given the fact that it will likely be years
before sufficient data on these tests has been
collected, how can insurance coverage of
these tests be implemented so that testing is
not a financial burden to patients?
Genetic Counseling
Challenges
• What should be included in pre-test counsel-
ing and informed consent for multiplexed
genetic tests? Since it is not feasible to pro-
vide for all tested conditions a clinical syn-
opsis, explanation of testing methodologies
and their limitations, and potential test out-
comes, what information is essential to
convey?
• How should the possibility of incidental
findings be addressed prior to testing?
• What communication methods tend to be most
effective in promoting patient retention of
large amounts of genetic information over
time?
• How will it be determined which test results
are “actionable” or merit further testing and
workup?
• Are there results that create a duty to recontact
the patient at a later time?
• What point-of-care tools will be useful in
promoting patient understanding of complex
test results?
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boards commonly used to engage local experts in discus-
sions of difficult cases in oncology.
Since some genetic tests are ordered routinely by non-
geneticists, it is important that GTIPs also include one or
more physicians in primary care, such as pediatrics or ob-
stetrics. Where applicable, GTIPs should also include ge-
netics professionals across multiple local institutions, to
encourage open exchange of ideas. If relevant experts are
not available locally, outside experts might be able to par-
ticipate by telephone or by computer using Skype or a
similar program. Since a primary aim of a GTIP is to foster
creative thinking about difficult questions, it is important to
have a range of disciplines and institutional perspectives
included. Lacking that diversity, GTIPs may simply perpet-
uate current thinking and be less likely to generate new
approaches to managing novel genetic tests.
We anticipate that many GTIPs will choose to focus on
global genetic testing issues, such as whether and how
genetic testing should be integrated into patient care. In
addition, similar to a tumor board, challenging patient-care
issues might be brought forward by GTIP members or non-
members for discussion. Nonetheless, discussions of actual
patient test reports by GTIPs should not take the place of a
clinically indicated genetics referral or further investigation
by the ordering physician or laboratory into the significance
of the test results. For example, if a neurologist orders a
chromosome microarray analysis and obtains an abnormal
result, the patient may benefit from a referral to a genetics
clinic for discussion of the clinical significance of the ge-
netic finding and to determine whether additional medical
evaluations or genetic testing of the patient and/or other
family members is indicated.
Based on experiences with our Working Groups, we also
recommend that GTIPs be limited to no more than ten to
twelve members. This number should accommodate most of
the relevant areas of expertise, while enabling good discus-
sion with all participants having an opportunity to partici-
pate. This target size is also reasonable since schedule
conflicts may arise and not all members will be able to
attend every GTIP meeting, resulting in a typical meeting
of eight to ten individuals, based on our research project
experience. In addition, designating a facilitator for each
meeting, who is responsible for preparing either a list of
specific issues to address or questions to discuss based on
relevant cases, can help to ensure success over time. Initial-
ly, a GTIP might meet quarterly or as determined by the
level of interest that exists among participants.
We believe genetic counselors are well positioned to
take the lead in establishing GTIPs at their institutions.
Genetic counselors are often responsible for researching
and coordinating genetic testing for patients and are
generally knowledgeable about who are some of the
experts at their institution, given their clinical roles
and skills at identifying resources. As experts in clinical
genetics, clinical geneticists and genetic counselors
should lead efforts to develop “best practices” and
guidelines for the use of DTC and other emerging
clinical genetic tests. In addition, establishing a GTIP
can serve other important functions, such as the promo-
tion of communication across genetics clinics and more
global discussions of appropriate genetic testing integra-
tion institutionally in specialties and primary care.
Fostering Intra-Institutional Dialogue and Laying
the Groundwork for Professional Standards
At an institutional level, genetics clinics may be in several
different departments. In each clinic, the types and numbers
of genetic tests ordered can vary significantly, with some
tests ordered regularly and others ordered periodically or
only on rare occasions. The test issues to address can also
vary depending on the clinic setting (e.g. prenatal versus
pediatric), the testing indication (e.g. symptomatic versus
asymptomatic), the patient, insurance coverage and other
factors. Even though clinics see different patient popula-
tions, there are genetic tests that are utilized across clinics
(e.g. testing for connective tissue disorders, such as Marfan
syndrome, may be done in prenatal, pediatric and adult
genetics clinics). Time and institutional politics may limit
general discussions about genetic testing practices. While
individual clinics may meet on a regular basis with their
clinical teams to go over cases and specific clinic issues,
there are few opportunities for all genetics clinics at an
institution to convene. There may be clinical genetics case
conferences and journal clubs but these forums generally do
not present opportunities to discuss the integration of genet-
ic advances into clinical practice and generally do not in-
volve non-geneticists. Time is already limited to address
specific clinical issues let alone think globally about how
genetic services and genetic testing should be integrated
more widely in healthcare. There can also be “turf” issues
as well, with some providers feeling that some genetic tests
are more squarely in their areas of expertise. GTIPs can
provide a safe harbor in which to examine what might
otherwise be viewed as a potentially divisive range of issues
around genetic testing.
Establishing a GTIP has the key benefit of bringing
together a diverse group of local experts to consider testing
issues. GTIPs provide an opportunity to highlight issues of
concern across genetic testing environments and provide a
recurrent forum in which to discuss these issues. GTIPs can
provide an effective venue for more general reflection about
the emergence of new forms of genomic testing and incor-
poration into patient care in addition to facilitating the
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development of strategies for addressing specific genetic
testing dilemmas.
Ongoing debates about the regulation of DTC tests have
highlighted how these tests raise issues that extend well
beyond patient management to include a broader range of
professional, ethical, and societal issues—and thus require
input from a more diverse set of experts than are typically
present in the day-to-day operations of a genetics clinic.
GTIPs can provide an institutional forum in which clinical
geneticists and genetic counselors can engage these difficult
questions in consultation with clinical genetics laboratory
directors and specialists in bioethics, health communication
and law. To the extent that the creation of formal practice
guidelines can take years, GTIPs may be viewed as a “stop
gap” approach that allows institutions to develop interim
guidance on the use of genetic tests in a more timely and
efficient manner.
Genetic Testing Integration Panels initially could be estab-
lished at individual institutions. Over time, if this model gains
wider acceptance, organizations such as the ACMG and
NSGC could provide resources to support GTIP efforts, in-
cluding a secure website to share discussion questions, discuss
outcomes, share GTIP recommendations, and disseminate key
documents and useful case studies. Open sharing of this
information would help save time for GTIPs and avoid dupli-
cation of efforts. GTIP members could also meet with other
GTIP members and ACMG leadership at annual conferences.
Genetic counselors who participate on GTIPs might also
consider forming a Special Interest Group (SIG) within NSGC
and could meet with NSGC leadership at annual conferences.
By sharing the work of GTIPs through a secure website and
through discussions with ACMG and NSGC leadership and
potentially through publications and submitted abstracts to
conferences, the work of GTIPs could be more widely dis-
seminated and provide information useful for the development
of practice guidelines. The GTIP model could also be adapted
more broadly in medicine through the formation of other
Testing Integration Panels (TIPs), potentially creating an ef-
fective forum for considering the integration of other new
diagnostic modalities, particularly in areas of medicine that
are changing quickly.
Potential Implementation Challenges
As an emerging model of professional deliberation, there are
several unresolved questions about how best to structure a
GTIP. One question is who should provide leadership on
these multidisciplinary panels. While a genetic counselor or
clinical geneticist could effectively facilitate a GTIP, based
on our experiences in the study described above, we recom-
mend that organizers consider the potential value added by
having these sessions led by an “outsider” to the relevant
genetics clinics. An outside advisor is unlikely to have
clinical interests in the resolution of practical questions,
which may allow that individual to lead meetings in an
unbiased way and provide a more impartial perspective if
tensions arise.
Given competing time demands, it is essential to consider
how to encourage participants’ attendance at GTIP meetings
and establish the “buy in” necessary to sustain these efforts
over time. At the outset, it will be critical that support from
genetics clinics be assessed, but as with any clinical endeavor,
the success of a GTIP will depend on the extent to which those
involved find it to be a useful activity that improves patient
care and thereby supports their personal involvement.
There are several other important issues to consider in
establishing GTIPs including: selection process and terms of
GTIP membership, procedures for determining GTIP meeting
agendas, development of clinical cases for discussion and
inclusion of cases by non-GTIP members, documentation of
GTIP meetings, and communication of GTIP deliberations
with relevant medical communities. To the extent that many
existing genetics clinics are located in major academic medi-
cal centers, we envision GTIPs beginning at these centers. As
experience is gained and the GTIP model is better developed
over time, this approach could be applied more broadly in
community-based hospitals and other clinical settings. Of
note, the GTIP model we propose as a starting point is based
on our earlier research project, which was done in several
academic medical centers. Successful translation of our GTIP
model to other clinical settings will require more experience
and potential modifications of this approach that leverage the
strengths of the local environment.
Conclusion
The fact is DTC genetic tests are here to stay and whole-
genome sequencing will become a clinical reality in a few
years. At this point in time, few of us in the genetics
community have had patients bring in DTC genetic test
results for interpretation or have had patients inquire about
this type of testing (Giovanni et al. 2010; Hock et al. 2011).
As we heard in our Working Groups, even genetics profes-
sionals may be overwhelmed by the amount of data in these
reports and find it difficult to interpret the data and effec-
tively communicate results to their patients. Specialists in
genetics need to be prepared to handle the vast amount of
genetic test results generated by these multiplex and DTC
tests and ensure that thoughtful consideration is given to the
potential integration of these tests into healthcare. Genetics
specialists also need to determine the types of genetic tests
that require genetics expertise to order and interpret versus
tests that can be ordered by other specialists and primary
care providers.
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The importance of establishing an institutional setting in
which these multidisciplinary discussions can occur is clear
when one considers the pace at which new diagnostic tech-
nologies and genetic tests are being introduced. This re-
markable expansion of genetic testing options makes it
very unlikely that an individual clinician will be able to
keep pace with the changes taking place in medical genetics.
The pace at which new genetic tests are emerging also
challenges traditional approaches to guiding clinical practi-
ces by expert review, such as the issuing of practice recom-
mendations by professional societies. Now is the time for
the genetics community to initiate more robust, practically
oriented conversations about the integration of new clinical
and DTC tests into patient care. Establishing a GTIP can
help clinicians address the gap in available practice guide-
lines and provide an effective forum for discussion of these
challenging and complex issues.
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